| Bid | 2.77 |
| Market Cap | 821.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -4.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.95 |
| Volume | 5,440,180 |
| Avg. Volume (20D) | 2,619,924 |
| Open | 3.04 |
| Previous Close | 3.00 |
| Day's Range | 2.75 - 3.06 |
| 52-Week Range | 2.33 - 5.62 |
| Beta | undefined |
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and...
Analyst Forecast
According to 3 analyst ratings, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 187.77% from the latest price.
Next Earnings Release
Analysts project revenue of $7.58M, reflecting a -17.42% YoY shrinking and earnings per share of -0.15, making a -6.25% decrease YoY.
2 months ago · seekingalpha.com
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call TranscriptAbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executiv...
